Why the study?
Does sildenafil added to conventional treatment improve RV mass, cardiac function, and exercise capacity in patients with PAH, WHO functional class III?
Does sildenafil added to conventional treatment improve RV mass, cardiac function, and exercise capacity in patients with PAH, WHO functional class III?
Sildenafil added to conventional treatment improves RV mass, cardiac function, and exercise capacity in patients with WHO functional class III PAH.
Supports sildenafil addition in WHO class III PAH; extends RCT evidence for RV-focused outcomes.
Sildenafil added to conventional treatment reduces RV mass and improves cardiac function and exercise capacity in patients with PAH, WHO functional class III. Safety monitoring is important until more experience is obtained.
No takes yet. Share an insight, caveat, or question.
Wilkins et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: